Gerkens, Sophie <br/><br/>
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.  [electronic resource] 

 -  Acta gastro-enterologica Belgica   
 - 177-87 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1784-3227 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alanine Transaminase--blood<br/>Antiviral Agents--administration & dosage<br/>Biomarkers--blood<br/>Cost-Benefit Analysis<br/>Dose-Response Relationship, Drug<br/>Drug Carriers<br/>Drug Costs<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Models, Economic<br/>Polyethylene Glycols--administration & dosage<br/>RNA, Viral--drug effects<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage<br/>Time Factors<br/>Treatment Outcome